|
Doug Gooding is a member of the Metastatix Board of Directors. He is also a Venture Partner at Aurora Funds.Doug serves as President at Regado Biosciences, one of Aurora’s portfolio companies. As a Venture Partner for Aurora, he works primarily with Aurora's life science portfolio, specifically in the areas of biotechnology, drug discovery and development. Doug also serves on the Board of Directors of Metabolon and Cropsolution.Prior to joining Aurora in 2001, he was a Director of Business Development at Paradigm Genetics (PDGM). Doug also spent four years at Incyte Pharmaceuticals (INCY), where he was the manager of the cDNA Library Construction Group. In addition, he worked as a Research Associate at Stratagene Cloning Systems in La Jolla, California.Doug received a Bachelor of Arts in Biology, with a minor in Chemistry, from the University of San Diego and a MBA from the Kenan-Flagler Business School in Chapel Hill, NC. | 